Comparative efficacy and safety of NALIRIFOX versus other first-line chemotherapy regimens in metastatic pancreatic ductal adenocarcinoma: a retrospective study
Open Access
- 22 May 2026
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Abstract
Background: Although gemcitabine plus nab-paclitaxel (Gem-NabP), modified FOLFIRINOX (mFOLFIRINOX), and NALIRIFOX are all recommended by current clinical guidelines as first-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC), the optimal regimen in real-world practice remains uncertain. Objective: To compare the efficacy and safety of different first-line chemotherapy regimens for mPDAC. Design: This was a single-center retrospective study. We included 215 patients with previously untreated mPDAC who received first-line chemotherapy at our institution between September 2023 and February 2025: Gem-NabP (n = 121), mFOLFIRINOX ( n = 55), and NALIRIFOX ( n = 39). Methods: The primary endpoints were progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), while overall survival (OS) was a secondary endpoint. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.1. Survival outcomes were analyzed using the Kaplan–Meier method and Cox proportional hazards models. Exploratory subgroup analyses were also performed. Results: NALIRIFOX showed the most favorable efficacy profile, with a median PFS of 9.0 months, a 6-month OS rate of 92.0%, an ORR of 30.77%, and a DCR of 89.74%, compared with 3.5 months, 74.6%, 18.18%, and 64.46% in the Gem-NabP group and 5.0 months, 82.6%, 16.36%, and 76.36% in the mFOLFIRINOX group, respectively (PFS, p < 0.001; ORR, p = 0.171; DCR, p = 0.007). Median OS was not reached in any group, and the between-group difference in OS was not statistically significant ( p = 0.062). In multivariable Cox analyses, both mFOLFIRINOX and NALIRIFOX remained associated with lower risks of disease progression and death than Gem-NabP, whereas alcohol consumption was independently associated with poorer survival. Toxicities were manageable across regimens, with most adverse events being Grade 1-2 and no treatment-related deaths. Grade ⩾3 adverse events were infrequent and generally comparable among groups. Exploratory analyses suggested a more favorable response distribution with NALIRIFOX in patients with mild-to-moderate cancer pain and those with tumors in the pancreatic head, neck, or tail. Conclusion: In this retrospective single-center cohort, NALIRIFOX was associated with longer PFS and favorable short-term survival, with manageable toxicity. These findings require validation in larger prospective multicenter studies.Keywords
Funding Information
- the Youth Innovation Team Development Program of Shandong Provincial Colleges (2024KJJ019 to R.Z.)
- Natural Science Foundation of Shandong Province (ZR2023ZD26, ZR2024JQ032, ZR2021YQ52)
- Natural Science Foundation of Shandong Province (ZR2025QC1761)
- Noncommunicable Chronic DiseasesNational Science and Technology Major Project (2024ZD0519900, 2024ZD0519902)
- National Natural Science Foundation of China (82172676, 82373217)
- Collaborative Academic Innovation Project of Shandong Cancer Hospital (GF001)
This publication has 34 references indexed in Scilit:
- Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersGastroenterology, 2019
- Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk FactorsWorld Journal of Oncology, 2019
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without ErlotinibJAMA, 2016
- Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)European Journal of Cancer, 2016
- Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experienceOncotarget, 2015
- Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient groupEuropean Journal of Medical Research, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Pancreatic Neuropathy and Neuropathic Pain—A Comprehensive Pathomorphological Study of 546 CasesGastroenterology, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007